ContraFect Corp (NASDAQ:CFRX) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 347,500 shares, a decline of 11.5% from the July 31st total of 392,500 shares. Based on an average daily volume of 487,700 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.6% of the company’s shares are sold short.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in shares of ContraFect in the 2nd quarter valued at approximately $343,000. Hartwell J M Limited Partnership increased its holdings in shares of ContraFect by 40.0% in the 2nd quarter. Hartwell J M Limited Partnership now owns 140,000 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 40,000 shares during the last quarter. White Pine Capital LLC increased its holdings in shares of ContraFect by 207.9% in the 1st quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 612,700 shares during the last quarter. Trellus Management Company LLC bought a new stake in shares of ContraFect in the 2nd quarter valued at approximately $295,000. Finally, Oracle Investment Management Inc. increased its holdings in shares of ContraFect by 13.1% in the 2nd quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock valued at $3,242,000 after acquiring an additional 735,450 shares during the last quarter. 34.86% of the stock is currently owned by institutional investors.

Shares of CFRX traded down $0.01 during trading on Friday, reaching $0.39. The company’s stock had a trading volume of 9,041 shares, compared to its average volume of 449,140. The company has a fifty day moving average of $0.40 and a two-hundred day moving average of $0.46. ContraFect has a twelve month low of $0.27 and a twelve month high of $2.63. The company has a market cap of $30.97 million, a price-to-earnings ratio of -1.07 and a beta of 0.15. The company has a quick ratio of 4.15, a current ratio of 4.15 and a debt-to-equity ratio of 0.37.

Several equities analysts recently commented on the company. ValuEngine raised ContraFect from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Maxim Group assumed coverage on ContraFect in a research report on Tuesday, June 11th. They set a “buy” rating on the stock.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

See Also: Do equity income investments outperform growth and income investments?

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.